StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The stock has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- High Flyers: 3 Natural Gas Stocks for March 2022
- MarketBeat Week in Review – 8/5 – 8/9
- Investing In Preferred Stock vs. Common Stock
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What are earnings reports?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.